News - Abgenix Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 13 /PRNewswire/ -- Portola Pharmaceuticals Inc. announced today that William R. Ringo, former president and CEO of Abgenix Inc., has been appointed to the company's Board of Directors.
Amgen (NASDAQ: AMGN) reported adjusted earnings per share (EPS), excluding stock option expense and certain other expenses, of $1.04 for the third quarter of 2006, an increase of 22 percent compared to 85 cents during the third quarter of 2005.
By Allison Bruce, Ventura County Star, Calif. Apr. 3--Amgen Inc. reported Monday positive test results for a potential blockbuster colorectal cancer drug that the company now owns outright after completing the purchase of smaller partner Abgenix Inc.
Amgen (Nasdaq: AMGN) and Abgenix, Inc. (Nasdaq: ABGX) today announced that Amgen has completed the Biologic License Application (BLA) submission with the U.S. Food and Drug Administration (FDA) for panitumumab.